Ipsen
Update in progressIPN.PA (Paris)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Ipsen S.A. is a Paris-based biopharmaceutical company focused on oncology, rare diseases, and neuroscience. It develops and markets medicines worldwide, including oncology drugs such as Somatuline, Cabometyx, Onivyde, Decapeptyl, Tazverik, and Tovorafenib, plus IPN01194/95. In rare diseases it markets Bylvay, Iqirvo, NutropinAq, Increlex, Fidrisertib, and Ritivixibat, and in neuroscience Dysport. Ipsen collaborates with Simcere for SIM0613.
Company score
- Sentiment
- 0.14
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.25
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.07
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.13
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!